TY - JOUR AU - Montalban, X. AU - Gold, R. AU - Thompson, A. J. PY - 2018 DA - 2018// TI - ECTRIMS/EAN guideline on the pharmacological treatment of people with multiple sclerosis JO - Eur J Neurol VL - 25 UR - https://doi.org/10.1111/ene.13536 DO - 10.1111/ene.13536 ID - Montalban2018 ER - TY - JOUR AU - Thompson, A. J. AU - Baranzini, S. E. AU - Geurts, J. AU - Hemmer, B. AU - Ciccarelli, O. PY - 2018 DA - 2018// TI - Multiple sclerosis JO - Lancet VL - 391 UR - https://doi.org/10.1016/S0140-6736(18)30481-1 DO - 10.1016/S0140-6736(18)30481-1 ID - Thompson2018 ER - TY - JOUR AU - Kobelt, G. AU - Thompson, A. AU - Berg, J. AU - Gannedahl, M. AU - Eriksson, J. PY - 2017 DA - 2017// TI - New insights into the burden and costs of multiple sclerosis in Europe JO - Mult Scler VL - 23 UR - https://doi.org/10.1177/1352458517694432 DO - 10.1177/1352458517694432 ID - Kobelt2017 ER - TY - JOUR AU - Lamore, R. AU - Jacob, E. AU - Jacob, S. C. AU - Hilas, O. PY - 2010 DA - 2010// TI - Dalfampridine (Ampyra): an aid to walking in patients with multiple sclerosis JO - P T Peer Rev J Formul Manag VL - 35 ID - Lamore2010 ER - TY - JOUR AU - Dobson, R. AU - Giovannoni, G. PY - 2019 DA - 2019// TI - Multiple sclerosis—a review JO - Eur J Neurol VL - 26 UR - https://doi.org/10.1111/ene.13819 DO - 10.1111/ene.13819 ID - Dobson2019 ER - TY - JOUR AU - Curtiss, F. R. PY - 2007 DA - 2007// TI - Pharmacoeconomic modeling of drug therapies for multiple sclerosis—are we building houses on sand? JO - J Manag Care Pharm VL - 13 UR - https://doi.org/10.18553/jmcp.2007.13.3.287 DO - 10.18553/jmcp.2007.13.3.287 ID - Curtiss2007 ER - TY - JOUR AU - Stockl, K. M. AU - Shin, J. S. AU - Gong, S. AU - Harada, A. S. AU - Solow, B. K. AU - Lew, H. C. PY - 2010 DA - 2010// TI - Improving patient self-management of multiple sclerosis through a disease therapy management program JO - Am J Manag Care VL - 16 ID - Stockl2010 ER - TY - JOUR AU - Hayes, K. C. PY - 2004 DA - 2004// TI - The use of 4-aminopyridine (fampridine) in demyelinating disorders JO - CNS Drug Rev VL - 10 UR - https://doi.org/10.1111/j.1527-3458.2004.tb00029.x DO - 10.1111/j.1527-3458.2004.tb00029.x ID - Hayes2004 ER - TY - STD TI - Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2018. https://www.accessdata.fda/gov. Cited 26 Sept 2018. Retrieved from: http://fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=022250. UR - http://fda.gov/scripts/cder/daf/index.cfm?event=overview.process&applno=022250 ID - ref9 ER - TY - JOUR AU - Shi, J. AU - Wu, X. AU - Chen, Y. PY - 2019 DA - 2019// TI - Study on dalfampridine in the treatment of Multiple Sclerosis Mobility Disability: a meta-analysis JO - PLoS ONE VL - 14 UR - https://doi.org/10.1371/journal.pone.0222288 DO - 10.1371/journal.pone.0222288 ID - Shi2019 ER - TY - JOUR AU - Valet, M. AU - Quoilin, M. AU - Lejeune, T. AU - Stoquart, G. AU - Pesch, V. AU - Sankari, S. PY - 2019 DA - 2019// TI - Effects of fampridine in people with multiple sclerosis: a systematic review and meta-analysis JO - CNS Drugs VL - 33 UR - https://doi.org/10.1007/s40263-019-00671-x DO - 10.1007/s40263-019-00671-x ID - Valet2019 ER - TY - JOUR AU - Polman, C. H. AU - Reingold, S. C. AU - Edan, G. AU - Filippi, M. AU - Hartung, H. P. AU - Kappos, L. PY - 2005 DA - 2005// TI - Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria” JO - Ann Neurol VL - 58 UR - https://doi.org/10.1002/ana.20703 DO - 10.1002/ana.20703 ID - Polman2005 ER - TY - JOUR AU - Polman, C. H. AU - Reingold, S. C. AU - Banwell, B. AU - Clanet, M. AU - Cohen, J. A. AU - Filippi, M. PY - 2011 DA - 2011// TI - Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria JO - Ann Neurol VL - 69 UR - https://doi.org/10.1002/ana.22366 DO - 10.1002/ana.22366 ID - Polman2011 ER - TY - JOUR AU - Kurtzke, J. F. PY - 1983 DA - 1983// TI - Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS) JO - Neurology VL - 33 UR - https://doi.org/10.1212/wnl.33.11.1444 DO - 10.1212/wnl.33.11.1444 ID - Kurtzke1983 ER - TY - JOUR AU - Hobart, J. AU - Ziemssen, T. AU - Feys, P. AU - Linnebank, M. AU - Goodman, A. D. AU - Farrell, R. PY - 2019 DA - 2019// TI - Assessment of clinically meaningful improvements in self-reported walking ability in participants with multiple sclerosis: results from the randomized, double-blind, Phase III ENHANCE trial of prolonged-release fampridine JO - CNS Drugs VL - 33 UR - https://doi.org/10.1007/s40263-018-0586-5 DO - 10.1007/s40263-018-0586-5 ID - Hobart2019 ER - TY - JOUR AU - Hupperts, R. AU - Lycke, J. AU - Short, C. AU - Gasperini, C. AU - McNeill, M. AU - Medori, R. PY - 2016 DA - 2016// TI - Prolonged-release fampridine and walking and balance in MS: randomised controlled MOBILE trial JO - Mult Scler VL - 22 UR - https://doi.org/10.1177/1352458515581436 DO - 10.1177/1352458515581436 ID - Hupperts2016 ER - TY - JOUR AU - Yapundich, R. AU - Applebee, A. AU - Bethoux, F. AU - Goldman, M. D. AU - Hutton, G. J. AU - Mass, M. PY - 2015 DA - 2015// TI - Evaluation of dalfampridine extended release 5 and 10 mg in Multiple Sclerosis: a randomized controlled trial JO - Int J MS Care VL - 17 UR - https://doi.org/10.7224/1537-2073.2014-040 DO - 10.7224/1537-2073.2014-040 ID - Yapundich2015 ER - TY - JOUR AU - Goodman, A. D. AU - Brown, T. R. AU - Edwards, K. R. AU - Krupp, L. B. AU - Schapiro, R. T. AU - Cohen, R. PY - 2010 DA - 2010// TI - A phase 3 trial of extended release oral dalfampridine in multiple sclerosis JO - Ann Neurol VL - 68 UR - https://doi.org/10.1002/ana.22240 DO - 10.1002/ana.22240 ID - Goodman2010 ER - TY - JOUR AU - Jensen, H. B. AU - Nielsen, J. L. AU - Ravnborg, M. AU - Dalgas, U. AU - Aagaard, P. AU - Stenager, E. PY - 2016 DA - 2016// TI - Effect of slow release-fampridine on muscle strength, rate of force development, functional capacity and cognitive function in an enriched population of MS patients. A randomized, double blind, placebo controlled study JO - Mult Scler Relat Disord VL - 10 UR - https://doi.org/10.1016/j.msard.2016.07.019 DO - 10.1016/j.msard.2016.07.019 ID - Jensen2016 ER - TY - JOUR AU - Jacques, F. AU - Schembri, A. AU - Nativ, A. AU - Paquette, C. AU - Kalinowski, P. PY - 2018 DA - 2018// TI - Prolonged-release fampridine as adjunct therapy to active motor training in MS Patients: a pilot, double-blind, randomized, placebo-controlled study JO - Mult Scler J Exp Transl Clin UR - https://doi.org/10.1177/2055217318761168 DO - 10.1177/2055217318761168 ID - Jacques2018 ER - TY - JOUR AU - Giglio, L. AU - Luca, F. AU - Gurreri, F. AU - Ferrante, I. AU - Prosperini, L. AU - Borriello, G. PY - 2019 DA - 2019// TI - Effect of dalfampridine on information processing speed impairment in multiple sclerosis JO - Neurology VL - 93 UR - https://doi.org/10.1212/WNL.0000000000007970 DO - 10.1212/WNL.0000000000007970 ID - Giglio2019 ER - TY - JOUR AU - Marion, S. AU - Leonid, C. AU - Belinda, B. AU - Joanne, D. AU - Elise, H. AU - Leeanne, C. PY - 2020 DA - 2020// TI - Effects of modified-release fampridine on upper limb impairment in patients with Multiple Sclerosis JO - Mult Scler Relat Disord VL - 40 UR - https://doi.org/10.1016/j.msard.2020.101971 DO - 10.1016/j.msard.2020.101971 ID - Marion2020 ER - TY - JOUR AU - Arreola-Mora, C. AU - Silva-Pereyra, J. AU - Fernández, T. AU - Paredes-Cruz, M. AU - Bertado-Cortés, B. AU - Grijalva, I. PY - 2019 DA - 2019// TI - Effects of 4-aminopyridine on attention and executive functions of patients with multiple sclerosis: randomized, double-blind, placebo-controlled clinical trial. Preliminary report [preliminary report] JO - Mult Scler Relat Disord VL - 28 UR - https://doi.org/10.1016/j.msard.2018.12.026 DO - 10.1016/j.msard.2018.12.026 ID - Arreola-Mora2019 ER - TY - JOUR AU - Hobart, J. AU - Blight, A. R. AU - Goodman, A. AU - Lynn, F. AU - Putzki, N. PY - 2013 DA - 2013// TI - Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS JO - Neurology VL - 80 UR - https://doi.org/10.1212/WNL.0b013e31828cf7f3 DO - 10.1212/WNL.0b013e31828cf7f3 ID - Hobart2013 ER - TY - JOUR AU - Sidovar, M. F. AU - Limone, B. L. AU - Coleman, C. I. PY - 2016 DA - 2016// TI - Mapping of Multiple Sclerosis Walking Scale (MSWS-12) to five-dimension EuroQol (EQ-5D) health outcomes: an independent validation in a randomized control cohort JO - Patient Relat Outcome Meas VL - 7 UR - https://doi.org/10.2147/PROM.S96956 DO - 10.2147/PROM.S96956 ID - Sidovar2016 ER - TY - JOUR AU - Kieseier, B. C. AU - Pozzilli, C. PY - 2012 DA - 2012// TI - Assessing walking disability in multiple sclerosis JO - Mult Scler VL - 18 UR - https://doi.org/10.1177/1352458512444498 DO - 10.1177/1352458512444498 ID - Kieseier2012 ER - TY - JOUR AU - Myhr, K. M. AU - Riise, T. AU - Vedeler, C. AU - Nortvedt, M. W. AU - Grønning, R. AU - Midgard, R. PY - 2001 DA - 2001// TI - Disability and prognosis in multiple sclerosis: demographic and clinical variables important for the ability to walk and awarding of disability pension JO - Mult Scler VL - 7 UR - https://doi.org/10.1177/135245850100700110 DO - 10.1177/135245850100700110 ID - Myhr2001 ER - TY - JOUR AU - Hemmett, L. AU - Holmes, J. AU - Barnes, M. AU - Russell, N. PY - 2004 DA - 2004// TI - What drives quality of life in multiple sclerosis? JO - Q J Med VL - 97 UR - https://doi.org/10.1093/qjmed/hch105 DO - 10.1093/qjmed/hch105 ID - Hemmett2004 ER - TY - JOUR AU - Edgley, K. AU - Sullivan, M. J. AU - Dehoux, E. PY - 1991 DA - 1991// TI - A survey of multiple sclerosis: II. Determinants of employment status JO - Can J Rehabil VL - 4 ID - Edgley1991 ER - TY - JOUR AU - Calkins, D. R. AU - Rubenstein, L. V. AU - Cleary, P. D. AU - Davies, A. R. AU - Jette, A. M. AU - Fink, A. PY - 1991 DA - 1991// TI - Failure of physicians to recognize functional disability in ambulatory patients JO - Ann Intern Med VL - 114 UR - https://doi.org/10.7326/0003-4819-114-6-451 DO - 10.7326/0003-4819-114-6-451 ID - Calkins1991 ER - TY - JOUR AU - Freeman, J. A. PY - 2001 DA - 2001// TI - Improving mobility and functional independence in persons with multiple sclerosis JO - J Neurol VL - 248 UR - https://doi.org/10.1007/s004150170198 DO - 10.1007/s004150170198 ID - Freeman2001 ER - TY - BOOK AU - McDonald, I. AU - Compston, A. PY - 2006 DA - 2006// TI - The symptoms and signs of multiple sclerosis PB - Churchill Livingstone CY - London UR - https://doi.org/10.1016/B978-0-443-07271-0.50008-2 DO - 10.1016/B978-0-443-07271-0.50008-2 ID - McDonald2006 ER - TY - JOUR AU - Kamm, C. P. AU - Heldner, M. R. AU - Vanbellingen, T. AU - Mattle, H. P. AU - Müri, R. AU - Bohlhalter, S. PY - 2012 DA - 2012// TI - Limb apraxia in multiple sclerosis: prevalence and impact on manual dexterity and activities of daily living JO - Arch Phys Med Rehabil VL - 93 UR - https://doi.org/10.1016/j.apmr.2012.01.008 DO - 10.1016/j.apmr.2012.01.008 ID - Kamm2012 ER - TY - JOUR AU - Koch, M. W. AU - Murray, T. J. AU - Fisk, J. AU - Greenfield, J. AU - Bhan, V. AU - Jacobs, P. PY - 2014 DA - 2014// TI - Hand dexterity and direct disease related cost in multiple sclerosis JO - J Neurol Sci VL - 341 UR - https://doi.org/10.1016/j.jns.2014.03.047 DO - 10.1016/j.jns.2014.03.047 ID - Koch2014 ER - TY - JOUR AU - Kalron, A. AU - Greenberg-Abrahami, M. AU - Gelav, S. AU - Achiron, A. PY - 2013 DA - 2013// TI - Effects of a new sensory re-education training tool on hand sensibility and manual dexterity in people with multiple sclerosis JO - NeuroRehabilitation VL - 32 UR - https://doi.org/10.3233/NRE-130917 DO - 10.3233/NRE-130917 ID - Kalron2013 ER - TY - JOUR AU - Kamm, C. P. AU - Mattle, H. P. AU - Müri, R. M. AU - Heldner, M. R. AU - Blatter, V. AU - Bartlome, S. PY - 2015 DA - 2015// TI - Home-based training to improve manual dexterity in patients with multiple sclerosis: a randomized controlled trial JO - Mult Scler VL - 21 UR - https://doi.org/10.1177/1352458514565959 DO - 10.1177/1352458514565959 ID - Kamm2015 ER - TY - JOUR AU - Hervault, M. AU - Balto, J. M. AU - Hubbard, E. A. AU - Motl, R. W. PY - 2017 DA - 2017// TI - Reliability, precision, and clinically important change of the Nine-Hole Peg Test in individuals with multiple sclerosis JO - Int J Rehabil Res VL - 40 UR - https://doi.org/10.1097/MRR.0000000000000209 DO - 10.1097/MRR.0000000000000209 ID - Hervault2017 ER - TY - JOUR AU - Allart, E. AU - Benoit, A. AU - Blanchard-Dauphin, A. AU - Tiffreau, V. AU - Thevenon, A. AU - Zephir, H. PY - 2015 DA - 2015// TI - Sustained-released fampridine in multiple sclerosis: effects on gait parameters, arm function, fatigue, and quality of life JO - J Neurol VL - 262 UR - https://doi.org/10.1007/s00415-015-7797-1 DO - 10.1007/s00415-015-7797-1 ID - Allart2015 ER - TY - JOUR AU - Jensen, H. B. AU - Ravnborg, M. AU - Dalgas, U. AU - Stenager, E. PY - 2014 DA - 2014// TI - 4-Aminopyridine for symptomatic treatment of multiple sclerosis: a systematic review JO - Ther Adv Neurol Disord VL - 7 UR - https://doi.org/10.1177/1756285613512712 DO - 10.1177/1756285613512712 ID - Jensen2014 ER - TY - JOUR AU - Pavsic, K. AU - Pelicon, K. AU - Ledinek, A. H. AU - Sega, S. PY - 2015 DA - 2015// TI - Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients JO - Clin Neurol Neurosurg VL - 139 UR - https://doi.org/10.1016/j.clineuro.2015.08.023 DO - 10.1016/j.clineuro.2015.08.023 ID - Pavsic2015 ER - TY - JOUR AU - Achiron, A. AU - Chapman, J. AU - Magalashvili, D. PY - 2013 DA - 2013// TI - Modeling of cognitive impairment by disease duration in multiple sclerosis: a cross-sectional study JO - PLoS ONE VL - 8 UR - https://doi.org/10.1371/journal.pone.0071058 DO - 10.1371/journal.pone.0071058 ID - Achiron2013 ER - TY - JOUR AU - Olazarán, J. AU - Cruz, I. AU - Benito-León, J. AU - Morales, J. M. AU - Duque, P. AU - Rivera-Navarro, J. PY - 2009 DA - 2009// TI - Cognitive dysfunction in multiple sclerosis: methods and prevalence from the GEDMA Study JO - Eur Neurol VL - 61 UR - https://doi.org/10.1159/000177940 DO - 10.1159/000177940 ID - Olazarán2009 ER - TY - JOUR AU - Rao, S. M. AU - Leo, G. J. AU - Bernardin, L. AU - Unverzagt, F. PY - 1991 DA - 1991// TI - Cognitive dysfunction in multiple sclerosis. I. Frequency, patterns, and prediction JO - Neurology VL - 41 UR - https://doi.org/10.1212/wnl.41.5.685 DO - 10.1212/wnl.41.5.685 ID - Rao1991 ER - TY - JOUR AU - Amato, M. P. AU - Krupp, L. B. AU - Charvet, L. E. AU - Penner, I. AU - Till, C. PY - 2016 DA - 2016// TI - Pediatric multiple sclerosis: cognition and mood JO - Neurology VL - 87 UR - https://doi.org/10.1212/WNL.0000000000002883 DO - 10.1212/WNL.0000000000002883 ID - Amato2016 ER - TY - JOUR AU - Julian, L. AU - Serafin, D. AU - Charvet, L. AU - Ackerson, J. AU - Benedict, R. AU - Braaten, E. PY - 2013 DA - 2013// TI - Cognitive impairment occurs in children and adolescents with multiple sclerosis: results from a United States network JO - J Child Neurol VL - 28 UR - https://doi.org/10.1177/0883073812464816 DO - 10.1177/0883073812464816 ID - Julian2013 ER - TY - JOUR AU - Bruce, J. M. AU - Hancock, L. M. AU - Arnett, P. AU - Lynch, S. PY - 2010 DA - 2010// TI - Treatment adherence in multiple sclerosis: association with emotional status, personality, and cognition JO - J Behav Med VL - 33 UR - https://doi.org/10.1007/s10865-010-9247-y DO - 10.1007/s10865-010-9247-y ID - Bruce2010 ER - TY - JOUR AU - Geisler, M. W. AU - Sliwinski, M. AU - Coyle, P. K. AU - Masur, D. M. AU - Doscher, C. AU - Krupp, L. B. PY - 1996 DA - 1996// TI - The effects of amantadine and pemoline on cognitive functioning in multiple sclerosis JO - Arch Neurol VL - 53 UR - https://doi.org/10.1001/archneur.1996.00550020101021 DO - 10.1001/archneur.1996.00550020101021 ID - Geisler1996 ER - TY - JOUR AU - Morrow, S. A. AU - Rosehart, H. AU - Johnson, A. M. PY - 2017 DA - 2017// TI - The effect of fampridine-SR on cognitive fatigue in a randomized double-blind crossover trial in patients with MS JO - Mult Scler Relat Disord VL - 11 UR - https://doi.org/10.1016/j.msard.2016.10.011 DO - 10.1016/j.msard.2016.10.011 ID - Morrow2017 ER - TY - JOUR AU - Sumowski, J. F. AU - Chiaravalloti, N. AU - Erlanger, D. AU - Kaushik, T. AU - Benedict, R. H. AU - DeLuca, J. PY - 2011 DA - 2011// TI - L-amphetamine improves memory in MS patients with objective memory impairment JO - Mult Scler VL - 17 UR - https://doi.org/10.1177/1352458511404585 DO - 10.1177/1352458511404585 ID - Sumowski2011 ER - TY - JOUR AU - Morrow, S. A. AU - Kaushik, T. AU - Zarevics, P. AU - Erlanger, D. AU - Bear, M. F. AU - Munschauer, F. E. PY - 2009 DA - 2009// TI - The effects of L-amphetamine sulfate on cognition in MS patients: results of a randomized controlled trial JO - J Neurol VL - 256 UR - https://doi.org/10.1007/s00415-009-5074-x DO - 10.1007/s00415-009-5074-x ID - Morrow2009 ER - TY - JOUR AU - Morrow, S. A. AU - Smerbeck, A. AU - Patrick, K. AU - Cookfair, D. AU - Weinstock-Guttman, B. AU - Benedict, R. H. PY - 2013 DA - 2013// TI - Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study JO - J Neurol VL - 260 UR - https://doi.org/10.1007/s00415-012-6663-7 DO - 10.1007/s00415-012-6663-7 ID - Morrow2013 ER - TY - JOUR AU - Peyro Saint Paul, L. AU - Creveuil, C. AU - Heinzlef, O. AU - Seze, J. AU - Vermersch, P. AU - Castelnovo, G. PY - 2016 DA - 2016// TI - Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: a randomized, placebo-controlled study JO - J Neurol Sci VL - 363 UR - https://doi.org/10.1016/j.jns.2016.02.012 DO - 10.1016/j.jns.2016.02.012 ID - Peyro Saint Paul2016 ER - TY - JOUR AU - Huolman, S. AU - Hämäläinen, P. AU - Vorobyev, V. AU - Ruutiainen, J. AU - Parkkola, R. AU - Laine, T. PY - 2011 DA - 2011// TI - The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue JO - Mult Scler VL - 17 UR - https://doi.org/10.1177/1352458511412061 DO - 10.1177/1352458511412061 ID - Huolman2011 ER - TY - JOUR AU - Krupp, L. B. AU - Christodoulou, C. AU - Melville, P. AU - Scherl, W. F. AU - MacAllister, W. S. AU - Elkins, L. E. PY - 2004 DA - 2004// TI - Donepezil improved memory in multiple sclerosis in a randomized clinical trial JO - Neurology VL - 63 UR - https://doi.org/10.1212/01.wnl.0000142989.09633.5a DO - 10.1212/01.wnl.0000142989.09633.5a ID - Krupp2004 ER - TY - JOUR AU - Jara, M. AU - Aquilina, T. AU - Aupperle, P. AU - Rabinowicz, A. L. PY - 2015 DA - 2015// TI - Safety profile of dalfampridine extended release in multiple sclerosis: 5-year postmarketing experience in the United States JO - Drug Healthc Patient Saf VL - 7 UR - https://doi.org/10.2147/DHPS.S97113 DO - 10.2147/DHPS.S97113 ID - Jara2015 ER - TY - STD TI - Food and Drug Administration. Drugs@FDA: FDA approved drug products. 2019. Cited 19 Dec 2019. Retrieved from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/22250s017lbl.pdf. UR - https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/22250s017lbl.pdf ID - ref56 ER - TY - JOUR AU - Pikoulas, T. E. AU - Fuller, M. A. PY - 2012 DA - 2012// TI - Dalfampridine: a medication to improve walking in patients with multiple sclerosis JO - Ann Pharmacother VL - 46 UR - https://doi.org/10.1345/aph.1Q714 DO - 10.1345/aph.1Q714 ID - Pikoulas2012 ER - TY - JOUR AU - Sumowski, J. F. AU - Benedict, R. AU - Enzinger, C. AU - Filippi, M. AU - Geurts, J. J. AU - Hamalainen, P. PY - 2018 DA - 2018// TI - Cognition in multiple sclerosis: state of the field and priorities for the future JO - Neurology VL - 90 UR - https://doi.org/10.1212/WNL.0000000000004977 DO - 10.1212/WNL.0000000000004977 ID - Sumowski2018 ER -